154 related articles for article (PubMed ID: 32268269)
1. Targeting CDC34 E2 ubiquitin conjugating enzyme for lung cancer therapy.
Zhang S; Sun Y
EBioMedicine; 2020 Apr; 54():102718. PubMed ID: 32268269
[No Abstract] [Full Text] [Related]
2. Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.
Tan YC; Mirzapoiazova T; Won BM; Zhu L; Srivastava MK; Vokes EE; Husain AN; Batra SK; Sharma S; Salgia R
Sci Rep; 2017 Aug; 7(1):9192. PubMed ID: 28835699
[TBL] [Abstract][Full Text] [Related]
3. Systematic identification of CDC34 that functions to stabilize EGFR and promote lung carcinogenesis.
Zhao XC; Wang GZ; Wen ZS; Zhou YC; Hu Q; Zhang B; Qu LW; Gao SH; Liu J; Ma L; Zhang YF; Zhang C; Yu H; Zhang DL; Wang M; Wang CL; Huang YC; Liu ZH; Zhao Y; Chen L; Zhou GB
EBioMedicine; 2020 Mar; 53():102689. PubMed ID: 32114396
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of E3 Ubiquitin Ligase CBLC Enhances EGFR Dysregulation and Signaling in Lung Adenocarcinoma.
Hong SY; Kao YR; Lee TC; Wu CW
Cancer Res; 2018 Sep; 78(17):4984-4996. PubMed ID: 29945960
[TBL] [Abstract][Full Text] [Related]
5. FGA isoform as an indicator of targeted therapy for EGFR mutated lung adenocarcinoma.
Shang Z; Niu X; Zhang K; Qiao Z; Liu S; Jiang X; Cao C; Lu S; Xiao H
J Mol Med (Berl); 2019 Dec; 97(12):1657-1668. PubMed ID: 31776635
[TBL] [Abstract][Full Text] [Related]
6. Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation.
Wiesweg M; Herold T; Metzenmacher M; Eberhardt WE; Reis H; Darwiche K; Aigner C; Stuschke M; Herrmann K; Nensa F; Schildhaus HU; Schuler M
Lung Cancer; 2020 Jan; 139():165-168. PubMed ID: 31809977
[TBL] [Abstract][Full Text] [Related]
7. UBE2S promotes the proliferation and survival of human lung adenocarcinoma cells.
Liu Z; Xu L
BMB Rep; 2018 Dec; 51(12):642-647. PubMed ID: 30545437
[TBL] [Abstract][Full Text] [Related]
8. Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.
Li M; Kales SC; Ma K; Shoemaker BA; Crespo-Barreto J; Cangelosi AL; Lipkowitz S; Panchenko AR
Cancer Res; 2016 Feb; 76(3):561-71. PubMed ID: 26676746
[TBL] [Abstract][Full Text] [Related]
9. Expression and Comparison of Cbl-b in Lung Squamous Cell Carcinoma and Adenocarcinoma.
Li P; Liu H; Zhang Z; Lv X; Wang H; Ma J; Ma Z; Qu X; Teng YE
Med Sci Monit; 2018 Jan; 24():623-635. PubMed ID: 29384143
[TBL] [Abstract][Full Text] [Related]
10. Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.
Ji Y; Schwartz J; Hartford A; Ramsey J; Phillips J; Verschraegen C
JAMA Oncol; 2015 Sep; 1(6):838-40. PubMed ID: 26181671
[No Abstract] [Full Text] [Related]
11. Construction of a transcription factor‑long non‑coding RNA‑microRNA network for the identification of key regulators in lung adenocarcinoma and lung squamous cell carcinoma.
Zhao S; Chen H; Ding B; Li J; Lv F; Han K; Zhou D; Yu B; Yu Y; Zhang W
Mol Med Rep; 2019 Feb; 19(2):1101-1109. PubMed ID: 30569133
[TBL] [Abstract][Full Text] [Related]
12. UBR-box containing protein, UBR5, is over-expressed in human lung adenocarcinoma and is a potential therapeutic target.
Saurabh K; Shah PP; Doll MA; Siskind LJ; Beverly LJ
BMC Cancer; 2020 Aug; 20(1):824. PubMed ID: 32867711
[TBL] [Abstract][Full Text] [Related]
13. Differential parsing of EGFR endocytic flux among parallel internalization pathways in lung cancer cells with EGFR-activating mutations.
Walsh AM; Lazzara MJ
Integr Biol (Camb); 2014 Mar; 6(3):312-23. PubMed ID: 24445374
[TBL] [Abstract][Full Text] [Related]
14. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
Lu GS; Li M; Xu CX; Wang D
Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
[TBL] [Abstract][Full Text] [Related]
15. BRM270 inhibits cancer stem cell maintenance via microRNA regulation in chemoresistant A549 lung adenocarcinoma cells.
Kwon T; Chandimali N; Huynh DL; Zhang JJ; Kim N; Bak Y; Yoon DY; Yu DY; Lee JC; Gera M; Ghosh M; Park YH; Jeong DK
Cell Death Dis; 2018 Feb; 9(2):244. PubMed ID: 29445170
[TBL] [Abstract][Full Text] [Related]
16. Clairvoyance or reliable prediction of the future?
van Zandwijk N; van de Vijver MJ
Ann Oncol; 2007 Mar; 18(3):407-8. PubMed ID: 17322538
[No Abstract] [Full Text] [Related]
17. Suppressed expression of Cbl-b by NF-κB mediates icotinib resistance in EGFR-mutant non-small-cell lung cancer.
Zhang T; Zheng C; Hou K; Wang J; Zhang Y; Fan Y; Zhao H; Qu X; Liu Y; Kang J; Che X; Hu X
Cell Biol Int; 2019 Feb; 43(2):98-107. PubMed ID: 29972257
[TBL] [Abstract][Full Text] [Related]
18. E2-c-Cbl recognition is necessary but not sufficient for ubiquitination activity.
Huang A; de Jong RN; Wienk H; Winkler GS; Timmers HT; Boelens R
J Mol Biol; 2009 Jan; 385(2):507-19. PubMed ID: 18996392
[TBL] [Abstract][Full Text] [Related]
19. E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer.
Wang S; Xu L; Che X; Li C; Xu L; Hou K; Fan Y; Wen T; Qu X; Liu Y
FEBS Lett; 2018 Feb; 592(4):621-630. PubMed ID: 29364514
[TBL] [Abstract][Full Text] [Related]
20. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
